| Literature DB >> 31207900 |
Angelika V Timofeeva1, Vitaliy V Chagovets2, Yulia S Drapkina3, Nataliya P Makarova4, Elena A Kalinina5, Gennady T Sukhikh6.
Abstract
Small noncoding RNAs (sncRNAs) are key regulators of the majority of human reproduction events. Understanding their function in the context of gametogenesis and embryogenesis will allow insight into the possible causes of in vitro fertilization (IVF) implantation failure. The aim of this study was to analyze the sncRNA expression profile of the spent culture media on day 4 after fertilization and to reveal a relationship with the morphofunctional characteristics of gametes and resultant embryos, in particular, with the embryo development and implantation potential. Thereto, cell-free, embryo-specific sncRNAs were identified by next generation sequencing (NGS) and quantified by reverse transcription coupled with polymerase chain reaction (RT-PCR) in real-time. Significant differences in the expression level of let-7b-5p, let-7i-5p, piR020401, piR16735, piR19675, piR20326, and piR17716 were revealed between embryo groups of various morphological gradings. Statistically significant correlations were found between the expression profiles of piR16735 and piR020401 with the oocyte-cumulus complex number, let-7b-5p and piR020401 with metaphase II oocyte and two pronuclei embryo numbers, let-7i-5p and piR20497 with the spermatozoid count per milliliter of ejaculate, piR19675 with the percentage of linearly motile spermatozoids, let-7b-5p with the embryo development grade, and let-7i-5p with embryo implantation. According to partial least squares discriminant analysis (PLS-DA), the expression levels of let-7i-5p (Variable Importance in Projection score (VIP) = 1.6262), piR020401 (VIP = 1.45281), and piR20497 (VIP = 1.42765) have the strongest influences on the implantation outcome.Entities:
Keywords: NGS; RT-PCR; embryo culture medium; miRNA; piRNA
Mesh:
Substances:
Year: 2019 PMID: 31207900 PMCID: PMC6627040 DOI: 10.3390/ijms20122912
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Venn diagrams for microRNA (miRNA) expression pattern (A) and piwi-interacting RNA (piRNA) expression pattern (B). The sncRNAs (miRNA and piRNA) unique to the blastocoele fluid are written in red; sncRNAs written in green are unique to the blastocyst spent culture medium by the fifth day after fertilization; sncRNAs are written in blue provided that they are detected both in the blastocoele fluid and in the blastocyst spent culture medium.
Small non-coding RNA (sncRNA) identification by next generation sequencing (NGS) and real time polymerase chain reaction (PCR) (if Ct > 35 cycles in most of the studied samples, these data were excluded from the analysis, “+”—data suitable for analysis).
| sncRNA | NGS Read Count (Blastocoele Liquid/Embryo Culture Medium) | 5′–3′ Sequence of Sense Primer, Tm (Melting Temperature) | PCR (Embryo Culture Medium) |
|---|---|---|---|
| hsa-let-7b-5p | 527/282 | Hs_let-7b_1 miScript Primer Assay, Cat.No. MS00003122, Tm = 55 °C | + |
| hsa-let-7a-5p | 537/258 | Hs_let-7a_2 miScript Primer Assay, Cat.No. MS00031220, Tm = 55 °C | Ct > 35 |
| hsa-miR-99a-5p | 351/145 | Hs_miR-99a_2 miScript Primer Assay, Cat.No. MS00032158, Tm = 55 °C | Ct > 35 |
| hsa-miR-148a-3p | 194/136 | Hs_miR-148a_1 miScript Primer Assay, Cat.No. MS00003556, Tm = 55 °C | Ct > 35 |
| hsa-let-7i-5p | 239/114 | Hs_let-7i_1 miScript Primer Assay, Cat.No. MS00003157, Tm = 55 °C | + |
| hsa-miR-26a-5p | 209/111 | Hs_miR-26a_2 miScript Primer Assay, Cat.No. MS00029239, Tm = 55 °C | Ct > 35 |
| hsa-let-7c-5p | 192/110 | Hs_let-7c_1 miScript Primer Assay, Cat.No. MS00003129, Tm = 55 °C | + |
| hsa-let-7g-5p | 145/89 | Hs_let-7g_2 miScript Primer Assay, Cat.No. MS00008337, Tm = 55 °C | Ct > 35 |
| hsa-miR-92a-3p | 144/91 | Hs_miR-92_1 miScript Primer Assay, Cat.No. MS00006594, Tm = 55 °C | + |
| hsa-miR-143-3p | 135/81 | Hs_miR-143_1 miScript Primer Assay, Cat.No. MS00003514, Tm = 55 °C | + |
| hsa-miR-125b-5p | 69/57 | Hs_miR-125b_1 miScript Primer Assay, Cat.No. MS00006629, Tm = 55 °C | Ct > 35 |
| hsa-miR-100-5p | 77/50 | Hs_miR-100_2 miScript Primer Assay, Cat.No. MS00031234, Tm = 55 °C | Ct > 35 |
| hsa-miR-125a-5p | 63/36 | Hs_miR-125a_1 miScript Primer Assay, Cat.No. MS00003423, Tm = 55 °C | Ct > 35 |
| hsa-miR-320a | 57/30 | Hs_miR-320a_1 miScript Primer Assay, Cat.No. MS00014707, Tm = 55 °C | Ct > 35 |
| hsa-miR-27b-3p | 56/28 | Hs_miR-27b_2 miScript Primer Assay, Cat.No. MS00031668, Tm = 55 °C | Ct > 35 |
| hsa-miR-200c-3p | 47/28 | Hs_miR-200c_1 miScript Primer Assay, Cat.No. MS00003752, Tm = 55 °C | Ct > 35 |
| Hsa-piR020401, DQ598029 | 0/23,808 | GGCTGGTCTCGAACTCCTGACCTCAGGT, Tm = 45 °C | + |
| Hsa-piR023338, DQ601914 | 0/27,727 | TAGTCCCAGCTACTTGGGAGGCTGAGGCA, Tm = 45 °C | + |
| Hsa-piR019675, DQ596992 | 2708/2645 | GCAATAACAGGTCTGTGATGCCCTTAGA, Tm = 53 °C | + |
| Hsa-piR016735, DQ593039 | 1676/1240 | CCTGGGAATACCGGGTGCTGTAGGCTTA, Tm = 50 °C | + |
| Hsa-piR017716, DQ594453 | 620/680 | TTCCCTGGTGGTCTAGTGGTTAGGATTCGGC, Tm = 45 °C | + |
| Hsa-piR020326, DQ597916 | 1810/2540 | GGCATTGGTGGTTCAGTGGTAGAATTCTCGC, Tm = 60 °C | + |
| Hsa-piR020497, DQ598177 | 291/350 | TGTAGCTCAGTGGTAGAGCGCGTGCT, Tm = 45 °C | + |
| Hsa-piR022296, DQ600515 | 0/10,609 | TACTCAGGAGGCTGAGGCAGGAGAATGGC, Tm = 45 °C | + |
Figure 2Two-dimensional hierarchical clustering of real-time RT-PCR data on sncRNAs from 87 embryo cultivation medium samples. E.q.—excellent quality, g.q.—good quality, f.q.—fair quality, p.q.—poor quality.
Figure 3sncRNA expression level fold change in the culture medium of embryos of different development grade. (A) sncRNA expression level fold change (FC) with values varying from 0.01 to 400 (data are presented on a logarithmic scale). (B) sncRNA expression level FC with values varying from 0.1 to 3.5 (data are presented on a linear scale). E.q.—excellent quality, g.q.—good quality, f.q.—fair quality, p.q.—poor quality.
Pairwise comparison of the fold changes in the expression level of sncRNAs in the sample groups shown in Figure 3.
| sncRNA | Group 1–Group 2 | Group 1, Me(Q1, Q3) * | Group 2, Me(Q1, Q3) * | |
|---|---|---|---|---|
| let-7b-5p | “3–10 cell embryon”–“morula” | 0.04 | 6.16 (4.08, 7.86) | 10.1 (6.42, 12.86) |
| “morula”–“fair quality blastocyst” | 0.02 | 10.1 (6.42, 12.86) | 4.18 (1.94, 6.71) | |
| “morula”–“excellent quality blastocyst” | 0.05 | 10.1 (6.42, 12.86) | 7.24 (3.48, 10.07) | |
| let-7i-5p | “morula”–“poor quality blastocyst” | 0.02 | 2.2 (0.87, 4.33) | 6.2 (5.19, 6.34) |
| “cavernous morula”–“poor quality blastocyst” | 0.01 | 3.17 (2.67, 3.89) | 6.2 (5.19, 6.34) | |
| “poor quality blastocyst”–“excellent quality blastocyst” | 0.01 | 6.2 (5.19, 6.34) | 3.26 (2.18, 4.52) | |
| piR020401 | “morula”–“fair quality blastocyst” | 0.02 | 2.12 (1.94, 2.2) | 1.92 (1.43, 2.01) |
| “fair quality blastocyst”–“good quality blastocyst” | <0.001 | 1.92 (1.43, 2.01) | 2.14 (2.05, 2.27) | |
| piR16735 | “3–10 cell embryon”–“cavernous morula” | <0.001 | 1.21 (1.21, 1.88) | 6.78 (3.97, 14.92) |
| “3–10 cell embryon”–“good quality blastocyst” | 0.01 | 1.21 (1.21, 1.88) | 6.3 (3.51, 8.2) | |
| “cavernous morula”–“fair quality blastocyst” | 0.04 | 6.78 (3.97, 14.92) | 1.74 (1.41, 3.85) | |
| “cavernous morula”–“excellent quality blastocyst” | 0.02 | 6.78 (3.97, 14.92) | 2.61 (1.62, 5.62) | |
| piR17716 | “poor quality blastocyst”–“good quality blastocyst” | 0.04 | 0.72 (0.69, 0.73) | 0.88 (0.73, 0.98) |
| piR19675 | “3–10 cell embryo”–“good quality blastocyst” | 0.02 | 0.1 (0.05, 0.36) | 1.26 (1.08, 1.63) |
| “3–10 cell embryo”–“excellent quality blastocyst” | 0.03 | 0.1 (0.05, 0.36) | 1.23 (0.7, 1.5) | |
| piR20326 | “3–10 cell embryo”–“good quality blastocyst” | 0.02 | 0.06 (0.04, 0.06) | 2.88 (1.09, 3.92) |
* The data are presented as medians (Me) and quartiles Q1 and Q3 in the format Me (Q1; Q3).
Figure 4Correlation matrix based on the non-parametric Spearman rank correlation method. Significant (p < 0.05) correlations are indicated by a dot, non-significant correlations are indicated by a cross, positive correlations are marked in blue, and negative correlations in red—the more significant the correlation, the larger the dot size. (A) Correlation analysis of the sncRNA expression level in 87 embryo cultivation medium samples and the quality of embryos. (B) Correlation analysis of the sncRNA expression level in 48 cultivation medium samples of embryos transferred to the uterus and the following parameters: fallopian tube presence—the presence of fallopian tubes in the female of each couple; sperm concentration—spermatozoid count per milliliter of ejaculate from the male of each couple; sperm motility—percentage of linearly motile spermatozoids from the male of each couple; sperm morphology—percentage of morphologically normal spermatozoids from the male of each couple; number of OCC—the number of oocyte–cumulus complexes from the female of each couple; number of M2—metaphase II oocyte number from the female of each couple; number of 2PN—two pronuclei embryo numbers from each couple; number of blastocysts—blastocyst number of each couple; pregnancy—the development of pregnancy after embryo transfer into the uterus; infertility factor—primary or secondary infertility in the female of each couple; hatching—embryo hatching before transfer to the uterine cavity; dev. gr.—embryo development stage and quality according to the Gardner grading scale; embryo morphology—morphological parameters of embryos according to the Gardner grading scale; M2/OCC, %—metaphase II oocyte number as a percentage of OCC; 2PN/M2, %—number of two pronuclei embryos as a percentage of M2 oocyte; blastocysts/2PN, %—blastocyst number as a percentage of 2PN embryos; blastocysts/OCC, %—blastocyst number as a percentage of OCC.
Figure 5Partial least squares discriminant analysis (PLS-DA) of 2−ΔΔCt RT-PCR data on the expression of sncRNAs in the 48-embryo culture medium samples. Arabic numerals denote the sample number. Roman numerals (I, II, III) denote the cluster of samples depending on the result of embryo transfer into the uterine cavity and the profile of RNA expression in the cultivation medium. (A) score plot with the imposition of information of the sncRNA expression level on the results of embryo transfer into the uterine cavity, (B) Variable Importance in Projection (VIP) score.
Genomic localization and potential piwiRNA target genes.
| Genbank ID | PiRBase ID for piRNAs | Location in hg38 * | RefSeq Gene | Repeat Information | Potential Gene Targets |
|---|---|---|---|---|---|
| hsa_piR_017716|gb|DQ594453|Homo | piR-hsa-24672, aliases piR-60565, PIR55564 | chr6_GL000255v2_alt:247775-247806: + | Name: tRNA-Glu-GAG, Family: tRNA, Class: tRNA | ||
| hsa_piR_020401|gb|DQ598029|Homo | piR-hsa-28244, aliases piR-36095 PIR59140 | chr6_GL000253v2_alt:2984874-2984902: − | LY6G5C NM_025262 | Name: AluSx, Family: Alu, Class: SINE |
|
| hsa_piR_016735|gb|DQ593039|Homo | piR-hsa-23317, aliases piR-33151 PIR54150 | chr6:4428052-4428083: + | Name: 5S, Family: rRNA, Class: rRNA | ||
| hsa_piR_019675|gb|DQ596992|Homo | piR-hsa-27282, aliases piR-35058 PIR58103 | chr14:89875053-89875081: − | EFCAB11 NM_001284269;NM_145231; NM_001284267 | Name: SSU-rRNA_Hsa, Family: rRNA, Class: rRNA |
|
| chr21:8211110-8211138: + | RNA18SN2 NR_146146; RNA18SN4 NR_146119; RNA18SN3 NR_146152; RNA18SN5 NR_003286; RNA45SN2 NR_146144; LOC100507412 NR_038958; RNA18SN1 NR_145820 | Name: SSU-rRNA_Hsa, Family: rRNA, Class: rRNA | |||
| chr21:8255319-8255347: + | RNA28SN5 NR_003287 | Name: SSU-rRNA_Hsa, Family: rRNA, Class: rRNA | |||
| chr21:8394145-8394173: + | LOC100507412 NR_038958; RNA28SN5 NR_003287; RNA18SN2 NR_146146; RNA18SN5 NR_003286; RNA45SN3 NR_146151; RNA18SN3 NR_146152; RNA18SN4 NR_146119; RNA18SN1 NR_145820; | Name: SSU-rRNA_Hsa, Family: rRNA, Class: rRNA | |||
| chr21:8438355-8438383: + | RNA45SN1 NR_145819; RNA18SN2 NR_146146; RNA45SN5 NR_046235; RNA18SN5 NR_003286; RNA18SN3 NR_146152; RNA18SN4 NR_146119; RNA18SN1 NR_145820; | Name: SSU-rRNA_Hsa, Family: rRNA, Class: rRNA | |||
| chr22_KI270733v1_random:127410-127438: + | RNA45SN1 NR_145819; RNA45SN5 NR_046235; RNA45SN2 NR_146144; RNA45SN4 NR_146117; RNA18SN5 NR_003286; RNA18SN3 NR_146152; RNA18SN4 NR_146119; RNA18SN2 NR_146146; RNA18SN1 NR_145820; | Name: SSU-rRNA_Hsa, Family: rRNA, Class: rRNA | |||
| chr22_KI270733v1_random:172491-172519: + | RNA18SN3 NR_146152; RNA18SN5 NR_003286; RNA18SN4 NR_146119; RNA18SN2 NR_146146; RNA18SN1 NR_145820; | Name: SSU-rRNA_Hsa, Family: rRNA, Class: rRNA | |||
| hsa_piR_020497|gb|DQ598177|Homo | piR-hsa-28392, aliases piR-36243 PIR59288 | chr6:28863725-28863757: −, chr6_GL000250v2_alt:129309-129341: −, chr6_GL000251v2_alt:354265-354297: −, chr6_GL000252v2_alt:129327-129359: −, chr6_GL000253v2_alt:129283-129315: −, chr6_GL000254v2_alt:129319-129351: −, chr6_GL000255v2_alt:129307-129339: −, chr6_GL000256v2_alt:172970-173002: − | Name: tRNA-Ala-GCY, Family: tRNA, Class: tRNA | ||
| hsa_piR_020326|gb|DQ597916|Homo | piR-hsa-28131, aliases piR-35982 PIR59027 | chr1:16545979-16546010: −, chr1:16861919-16861950: + | Name: tRNA-Gly-GGG, Family: tRNA, Class: tRNA | ||
| chr16:70789505-70789536: + | VAC14 NM_001351157, NM_018052 | Name: tRNA-Gly-GGY, Family: tRNA, Class: tRNA | |||
| chr3:15507990-15508021: + | COLQ NM_080539, NM_005677 | Name: tRNA-Gly-GGG, Family: tRNA, Class: tRNA | |||
| chr6:27902948-27902979: − | Name: tRNA-Gly-GGY, Family: tRNA, Class: tRNA | ||||
| hsa_piR_022296|gb|DQ600515|Homo | piR-hsa-30715, aliases piR-38581 PIR61626 | chr18:13769187-13769216: + | Name: AluY, Family: Alu, Class: SINE |
| |
| hsa_piR_023338|gb|DQ601914|Homo | piR-hsa-30937, aliases piR-39980 PIR63025 | chr17:42974237-42974266: + | PTGES3L NM_001142654, NM_001142653, NM_001261430; PTGES3L-AARSD1 NM_025267, NM_001136042; | Name: AluSq, Family: Alu, Class: SINE |
* ”+” denotes sense strand which contains the exact nucleotide sequence to the messenger RNA (Mrna); “−“ denotes antisense strand, serves as the template for the transcription and contains complementary nucleotide sequence to the transcribed mRNA.
Predicted and experimentally supported miRNA targets.
|
| |||
|
|
|
|
|
| ECM–receptor interaction | < 1 × 10−325 | 15 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Mucin type O-Glycan biosynthesis | 4.21 × 10−11 | 5 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p |
| Glycosaminoglycan biosynthesis—chondroitin sulfate/dermatan sulfate | 8.44 × 10−8 | 4 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p |
| Amoebiasis | 2.48 × 10−7 | 11 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p |
| Signaling pathways regulating stem cell pluripotency | 1.19 × 10−5 | 16 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p |
| Protein digestion and absorption | 0.006789 | 11 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p |
| PI3K-Akt signaling pathway | 0.009286 | 27 | hsa-let-7b-5p, hsa-let-7c-5p |
| Wnt signaling pathway | 0.017555 | 11 | hsa-let-7c-5p |
|
| |||
| Mucin type O-Glycan biosynthesis (hsa00512) | 4.43 × 10−12 | 1 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p |
| Valine, leucine, and isoleucine biosynthesis (hsa00290) | 1.79 × 10−8 | 1 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p |
| Signaling pathways regulating stem cell pluripotency (hsa04550) | 7.77 × 10−6 | 6 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p |
| Biosynthesis of amino acids (hsa01230) | 0.000132 | 2 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p |
| 2-Oxocarboxylic acid metabolism (hsa01210) | 0.000166 | 1 | hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7i-5p |
| Oocyte meiosis (hsa04114) | 0.008317 | 3 | hsa-let-7b-5p, hsa-let-7c-5p |
| Valine, leucine, and isoleucine degradation (hsa00280) | 0.026219 | 1 | hsa-let-7c-5p |
| Arginine and proline metabolism (hsa00330) | 0.026219 | 2 | hsa-let-7c-5p |
|
| |||
| Lysine degradation (hsa00310) | 6.06959 × 10−13 | 20 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Cell cycle (hsa04110) | 1.13021 × 10−11 | 52 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Viral carcinogenesis (hsa05203) | 5.62537 × 10−10 | 60 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Hepatitis B (hsa05161) | 5.35744 × 10−08 | 54 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Oocyte meiosis (hsa04114) | 1.75682 × 10−07 | 41 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Chronic myeloid leukemia (hsa05220) | 2.5576 × 10−7 | 27 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Hippo signaling pathway (hsa04390) | 4.05654 × 10−7 | 50 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Proteoglycans in cancer (hsa05205) | 1.70389 × 10−6 | 64 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Thyroid hormone signaling pathway (hsa04919) | 2.7327 × 10−6 | 39 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Adherens junctions (hsa04520) | 3.42243 × 10−6 | 30 | hsa-let-7i-5p, hsa-miR-92a-3p |
| FoxO signaling pathway (hsa04068) | 2.15597 × 10−5 | 50 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| ECM–receptor interaction (hsa04512) | 2.47672 × 10−5 | 12 | hsa-let-7i-5p |
| Bacterial invasion of epithelial cells (hsa05100) | 4.61176 × 10−5 | 28 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Glioma (hsa05214) | 7.08143 × 10−5 | 20 | hsa-let-7b-5p, hsa-let-7i-5p |
| Pathways in cancer (hsa05200) | 0.000154251 | 99 | hsa-let-7i-5p, hsa-miR-92a-3p |
| Colorectal cancer (hsa05210) | 0.000634129 | 25 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Thyroid cancer (hsa05216) | 0.000693712 | 12 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Prostate cancer (hsa05215) | 0.001016403 | 35 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Epstein–Barr virus infection (hsa05169) | 0.002168481 | 51 | hsa-let-7b-5p, hsa-let-7i-5p |
| MAPK signaling pathway (hsa04010) | 0.003378721 | 59 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Endocytosis (hsa04144) | 0.003828609 | 62 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| Huntington’s disease (hsa05016) | 0.003922408 | 50 | hsa-let-7b-5p, hsa-miR-92a-3p |
| Small cell lung cancer (hsa05222) | 0.004508148 | 24 | hsa-let-7b-5p, hsa-let-7i-5p |
| TGF-beta signaling pathway (hsa04350) | 0.006182085 | 29 | hsa-let-7b-5p, hsa-let-7i-5p, hsa-miR-92a-3p |
| p53 signaling pathway (hsa04115) | 0.007856274 | 20 | hsa-let-7b-5p, hsa-let-7i-5p |
| Melanoma (hsa05218) | 0.008148048 | 18 | hsa-let-7b-5p, hsa-let-7i-5p |
| Shigellosis (hsa05131) | 0.009612655 | 13 | hsa-miR-92a-3p |
| Bladder cancer (hsa05219) | 0.009747186 | 14 | hsa-let-7b-5p, hsa-let-7i-5p |
| Signaling pathways regulating pluripotency of stem cells (hsa04550) | 0.01296196 | 26 | hsa-miR-92a-3p |
| Estrogen signaling pathway (hsa04915) | 0.01345837 | 17 | hsa-let-7i-5p |
| Transcriptional misregulation in cancer (hsa05202) | 0.01729337 | 45 | hsa-let-7i-5p, hsa-miR-92a-3p |
| Ubiquitin mediated proteolysis (hsa04120) | 0.01776272 | 34 | hsa-let-7b-5p |
| Protein processing in endoplasmic reticulum (hsa04141) | 0.02539808 | 38 | hsa-let-7b-5p, hsa-let-7i-5p |
| RNA transport (hsa03013) | 0.02748059 | 41 | hsa-let-7b-5p |
| Valine, leucine and isoleucine biosynthesis (hsa00290) | 0.03746544 | 2 | hsa-miR-92a-3p |
Figure 6Functional classification of genes targeted by let-7b-5p, let-7c-5p, let-7i-5p, and miR-92a-3p from miRtargetlink and the PANTHER databases.
Comparison of the clinical and demographic characteristics of patients enrolled in the current study.
| Clinical and Demographic Characteristics | Group I (Implantation Failure)—25 Patients | Group II (Successful Implantation)—14 Patients | Group III (Successful Implantation in A Frozen Embryo Transfer Protocol)—4 Patients |
|
|---|---|---|---|---|
| Body mass index (BMI) * | 22.1 (2.0) | 22.2 (1.4) | 22.0 (1.8) | >0.05 |
| Menstrual cycle length (days) * | 29.9 (1.6) | 28.4 (0.9) | 29.0 (2.7) | >0.05 |
| Average age (years) * | 32.3 (3.5) | 32.0 (3.1) | 30.0 (2.4) | >0,05 |
| Follicle-stimulating hormone level on day 2–3 of menstrual cycle (mIU/mL) * | 7.8 (1.4) | 7.2 (1.4) | 5.8 (0.5) | >0.05 |
| Anti-mullerian hormone level (ng/mL) * | 2.4 (1.0) | 2.4 (0.7) | 2.8 (0.5) | >0.05 |
| Antral follicle count on day 2–3 of the menstrual cycle * | 8.2 (1.6) | 7.8 (1.5) | 8.3 (1.0) | >0.05 |
| Male factor infertility ** | 18 patients (64%) had male factor infertility | 14 patients (78%) had male factor infertility | 2 patients (50%) had male factor infertility | >0.05 |
| Primary infertility ** | 13 patients (46%) had primary infertility | 8 patients (44%) had primary infertility | 2 patients (50%) had primary infertility | >0.05 |
| Assisted hatching ** | In 20 (71%) patients, assisted hatching was performed | In 10 (56%) patients, assisted hatching was performed | In 2 (50%) patients, assisted hatching was performed | >0.05 |
| Number of oocytes retrieved * | 7.8 (3.7) | 7.4 (4.5) | 8.0 (3.7) | >0.05 |
| Number of blastocysts * | 1.4 (1.3) | 1.4 (1.2) | 2.8 (2.0) | >0.05 |
* Data are presented as an arithmetic mean (M) and standard deviation (SD) in the format of M(SD), specifying the significant differences when using ANOVA test; ** data are presented as absolute N numbers and percentages of the total number of patients in group P in the format of N(P%), specifying the significant differences when using the χ2 test. Comment: Group III (successful implantation in a frozen embryo transfer protocol) coincides with Group I (implantation failure), since patients from Group I were transferred to Group III after their previous failed IVF.